Figure S1. Crizotinib alters H1650 cell viability and metabolism. Treatment with (A) 1 μM crizotinib decreased H1650 cell viability (A), and (B) increased glucose consumption and (C) lactate content. (D) Treatment with 1 μM crizotinib attenuated ATP production.



Figure S2. Representative histograms of EdU fluorescence in A549 cells after treatment with crizotinib and three inhibitors (2-DG, rotenone and MG132).



Figure S3. Representative flow cytometry analysis of JC-1 green fluorescence after treatment with 1 μM crizotinib and three inhibitors (2DG, rotenone and MG132).